Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.21M Buy
45,922
+7,549
+20% +$385K 0.09% 232
2026
Q2
$2.01M Sell
38,373
-7,184
-16% -$380K 0.08% 249
2026
Q1
$2.51M Sell
45,557
-4,434
-9% -$240K 0.11% 181
2025
Q4
$2.45M Buy
49,991
+38,308
+328% +$1.79M 0.11% 182
2025
Q3
$504K Sell
11,683
-1,010
-8% -$39.5K 0.04% 382
2025
Q2
$487K Sell
12,693
-451
-3% -$17.2K 0.04% 366
2025
Q1
$509K Sell
13,144
-1,047
-7% -$38.3K 0.04% 327
2024
Q4
$480K Sell
14,191
-2,066
-13% -$74.4K 0.04% 347
2024
Q3
$665K Buy
+16,257
New +$665K 0.06% 280

Other funds holding GSK

BFC Planning's GSK Position: Q3 2026 in Review

BFC Planning increased its GSK (GSK) stake by 20% in Q3 2026, buying an estimated $385K and bringing the position to 45,922 shares worth $2.21M. The position accounts for 0.09% of the portfolio, ranked #232.

BFC Planning first reported a position in GSK in Q3 2024 and has held it in 9 quarters since. The position peaked at $2.51M in Q1 2026. 854 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • BFC Planning held 45,922 shares of GSK worth $2.21M as of Q3 2026.
  • BFC Planning bought 7,549 GSK shares in Q3 2026, an estimated $385K.
  • GSK made up 0.09% of BFC Planning's portfolio in Q3 2026, its #232 holding.
  • BFC Planning first reported a position in GSK in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's GSK position peaked at $2.51M in Q1 2026.
  • 854 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.